TY - JOUR
T1 - Individual Prediction of Remission Based on Clinical Features Following Electroconvulsive Therapy
T2 - A Machine Learning Approach
AU - Nakajima, Kazuki
AU - Takamiya, Akihiro
AU - Uchida, Takahito
AU - Kudo, Shun
AU - Nishida, Hana
AU - Minami, Fusaka
AU - Yamamoto, Yasuharu
AU - Yamagata, Bun
AU - Mimura, Masaru
AU - Hirano, Jinichi
N1 - Funding Information:
Submitted: October 17, 2021; accepted April 4, 3. Rush AJ, Aaronson ST, Demyttenaere K. and amygdala volumes: systematic review and 2022. Difficult-to-treat depression: A clinical and meta-analysis.Br J Psychiatry. Publishedonline:August 24, 2022 research roadmap for when remission is 2018;212(1):19–26.PubMed CrossRef Authorcontributions:DrsNakajima,Takamiya, elusive. Aust N Z J Psychiatry. Takamiya A, Plitman E, Chung JK, et al. Acute and Hirano were critically involved in the data 2019;53(2):109–118.PubMed CrossRef and long-term effects of electroconvulsive analysis and wrote the first draft ofthe manuscript. 4. UK ECT Review Group. Efficacy and safety of therapy on human dentate gyrus. DrsUchida,Kudo,Minami,Yamamoto,and electroconvulsive therapy in depressive Neuropsychopharmacology. Nishida contributed to the interpretation ofthe disorders: a systematic review and meta-2019;44(10):1805–1811.PubMed CrossRef data. Drs Mimura andYamagata supervised the analysis. Lancet. 2003;361(9360):799–808.PubMed CrossRef Takamiya A, Kishimoto T, Hirano J, et al. entire project and were critically involved in the 5. Kellner CH, Greenberg RM, Murrough JW, et al. Association of electroconvulsive therapy-design and interpretation ofthe data. All authors ECT in treatment-resistant depression. Am J induced structural plasticity with clinical contributed to and approved the final manuscript. Psychiatry. 2012;169(12):1238–1244.PubMed CrossRef remission. Prog Neuropsychopharmacol Biol 6. Kellner CH, Obbels J, Sienaert P. When to Psychiatry. 2021;110:110286.PubMed CrossRef Relevantfinancialrelationships:The authors consider electroconvulsive therapy (ECT). Acta van Diermen L, van den Ameele S, Kamperman declare no conflicts of interest. Psychiatr Scand. 2020;141(4):304–315.PubMed CrossRef AM, et al. Prediction of electroconvulsive Funding/support:This study was supported 7. Semkovska M, McLoughlin DM. Objective therapy response and remission in major by the Japan Agency for Medical Research and cognitive performance associated with depression: meta-analysis. Br J Psychiatry. Development (AMED) under Grant Number electroconvulsive therapy for depression: a 2018;212(2):71–80.PubMed CrossRef JP21dm0307102h0003, by the Japan Society for the systematic review and meta-analysis. Biol Haq AU, Sitzmann AF, Goldman ML, et al. Promotion of Science (JSPS) KAKENHI under Grant Psychiatry. 2010;68(6):568–577.PubMed CrossRef Response of depression to electroconvulsive Numbers17K10315and21K07551,and by the Daiwa 8. Vasavada MM, Leaver AM, Njau S, et al. Short-therapy: a meta-analysis of clinical predictors. SecuritiesHealthFoundation. and long-term cognitive outcomes in patients J Clin Psychiatry. 2015;76(10):1374–1384.PubMed CrossRef Role of the sponsor: The supporters had no role in with major depression treated with Abbott CC, Loo D, Sui J. Determining the design, analysis, interpretation, or publication electroconvulsive therapy. J ECT. electroconvulsive therapy response with of this study. 2017;33(4):278–285.PubMed CrossRef machine learning. JAMA Psychiatry. Acknowledgments:The authors thank A. Hamada, 9. Sackeim HA. Modern electroconvulsive 2016;73(6):545–546.PubMed CrossRef MD; M. Inaoka, MD; M. Isobe, MD; S. Katayama, MD; therapy: vastly improved yet greatly Bzdok D, Varoquaux G, Steyerberg EW. Y.Kikuchi, MD; S. Kurose, MD; N. Nitta, MD; H. Oi, underused. JAMA Psychiatry. Prediction, not association, paves the road to MD; M. Sakuma, MD; K. Sawada, MD;Y.Shimomura, 2017;74(8):779–780.PubMed CrossRef precision medicine. JAMA Psychiatry. MD; A. Shiomi, MD; S. Takasu, MD; M. Wada, MD; N. Takamiya A, Sawada K, Mimura M, et al. 2021;78(2):127–128.PubMed CrossRef Waki, MD; R. Watanabe, MD; M. Kimura, MD; and Attitudes toward electroconvulsive therapy Ryu S, Lee H, Lee DK, et al. Detection of suicide T. Yatomi, MD, for data collection. All are from the among involuntary and voluntary patients. attempters among suicide ideators using Department of Neuropsychiatry, Keio University J ECT. 2019;35(3):165–169.PubMed CrossRef machine learning. Psychiatry Investig. School of Medicine, Tokyo, Japan, and have no Abbott CC, Gallegos P, Rediske N, et al. A 2019;16(8):588–593.PubMed CrossRef conflicts of interest to declare. review of longitudinal electroconvulsive Takamiya A, Liang KC, Nishikata S, et al. therapy: neuroimaging investigations. J Geriatr Predicting individual remission after PsychiatryNeurol. 2014;27(1):33–46.PubMedCrossRef electroconvulsivetherapybasedonstructural 12. Bolwig TG. Neuroimaging and magnetic resonance imaging: A machine 1. World Health Organization. https://www.who. electroconvulsive therapy: a review. J ECT. learning approach. J ECT. 2020;36(3):205–210.PubMed CrossRef int/en/news-room/fact-sheets/detail/ 2014;30(2):138–142.PubMed CrossRef Leaver AM, Wade B, Vasavada M, et al. Fronto-depression. 2021. Accessed September 18, 2021 Bouckaert F, Sienaert P, Obbels J, et al. ECT: its temporal connectivity predicts ECT outcome 2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute brain enabling effects: a review of inmajordepression.Front Psychiatry. and longer-term outcomes in depressed electroconvulsive therapy-induced structural 2018;9:92.PubMed CrossRef outpatients requiring one or several treatment brain plasticity. J ECT. 2014;30(2):143–151.PubMed CrossRef Wang J, Wei Q, Bai T, et al. Electroconvulsive steps: a STAR*D report. Am J Psychiatry. Takamiya A, Chung JK, Liang KC, et al. Effect of therapyselectivelyenhancedfeedforward 2006;163(11):1905–1917.PubMed CrossRef electroconvulsive therapy on hippocampal connectivity from fusiform face area to
Funding Information:
This study was supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP21dm0307102h0003, by the Japan Society for the Promotion of Science (JSPS) KAKENHI under Grant Numbers 17K10315 and 21K07551, and by the Daiwa Securities Health Foundation.
Publisher Copyright:
© 2022 Physicians Postgraduate Press, Inc.
PY - 2022/9
Y1 - 2022/9
N2 - Objective: Previous prediction models for electroconvulsive therapy (ECT) responses have predominantly been based on neuroimaging data, which has precluded widespread application for severe cases in real-world clinical settings. The aims of this study were (1) to build a clinically useful prediction model for ECT remission based solely on clinical information and (2) to identify influential features in the prediction model. Methods: We conducted a retrospective chart review to collect data (registered between April 2012 and March 2019) from individuals with depression (unipolar major depressive disorder or bipolar disorder) diagnosed via DSM-IV-TR criteria who received ECT at Keio University Hospital. Clinical characteristics were used as candidate features. A light gradient boosting machine was used for prediction, and 5-fold cross-validation was performed to validate our prediction model. Results: In total, 177 patients with depression underwent ECT during the study period. The remission rate was 63%. Our model predicted individual patient outcomes with 71% accuracy (sensitivity, 86%; specificity, 46%). A shorter duration of the current episodes, lower baseline severity, higher dose of antidepressant medications before ECT, and lower body mass index were identified as important features for predicting remission following ECT. Conclusions: We developed a prediction model for ECT remission based solely on clinical information. Our prediction model demonstrated accuracy comparable to that in previous reports. Our model suggests that introducing ECT earlier in the treatment course may contribute to improvements in clinical outcomes.
AB - Objective: Previous prediction models for electroconvulsive therapy (ECT) responses have predominantly been based on neuroimaging data, which has precluded widespread application for severe cases in real-world clinical settings. The aims of this study were (1) to build a clinically useful prediction model for ECT remission based solely on clinical information and (2) to identify influential features in the prediction model. Methods: We conducted a retrospective chart review to collect data (registered between April 2012 and March 2019) from individuals with depression (unipolar major depressive disorder or bipolar disorder) diagnosed via DSM-IV-TR criteria who received ECT at Keio University Hospital. Clinical characteristics were used as candidate features. A light gradient boosting machine was used for prediction, and 5-fold cross-validation was performed to validate our prediction model. Results: In total, 177 patients with depression underwent ECT during the study period. The remission rate was 63%. Our model predicted individual patient outcomes with 71% accuracy (sensitivity, 86%; specificity, 46%). A shorter duration of the current episodes, lower baseline severity, higher dose of antidepressant medications before ECT, and lower body mass index were identified as important features for predicting remission following ECT. Conclusions: We developed a prediction model for ECT remission based solely on clinical information. Our prediction model demonstrated accuracy comparable to that in previous reports. Our model suggests that introducing ECT earlier in the treatment course may contribute to improvements in clinical outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85137125253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137125253&partnerID=8YFLogxK
U2 - 10.4088/JCP.21m14293
DO - 10.4088/JCP.21m14293
M3 - Article
C2 - 36005893
AN - SCOPUS:85137125253
SN - 0160-6689
VL - 83
JO - Diseases of the Nervous System
JF - Diseases of the Nervous System
IS - 5
M1 - 21m14293
ER -